Literature DB >> 29365318

Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice.

Seema R Patel1, Ashley Bennett1, Kathryn Girard-Pierce1, Cheryl L Maier1, Satheesh Chonat1,2, Connie M Arthur1, Patricia E Zerra1,2, Amanda Mener1, Sean R Stowell1.   

Abstract

Individuals that become immunized to red blood cell (RBC) alloantigens can experience an increased rate of antibody formation to additional RBC alloantigens following subsequent transfusion. Despite this, how an immune response to one RBC immunogen may impact subsequent alloimmunization to a completely different RBC alloantigen remains unknown. Our studies demonstrate that Kell blood group antigen (KEL) RBC transfusion in the presence of inflammation induced by poly (I:C) (PIC) not only enhances anti-KEL antibody production through a CD4+ T-cell-dependent process but also directly facilitates anti-HOD antibody formation following subsequent exposure to the disparate HOD (hen egg lysozyme, ovalbumin, fused to human blood group antigen Duffy b) antigen. PIC/KEL priming of the anti-HOD antibody response required that RBCs express both the KEL and HOD antigens (HOD × KEL RBCs), as transfusion of HOD RBCs plus KEL RBCs or HOD RBCs alone failed to impact anti-HOD antibody formation in recipients previously primed with PIC/KEL. Transfer of CD4+ T cells from PIC/KEL-primed recipients directly facilitated anti-HOD antibody formation following (HOD × KEL) RBC transfusion. RBC alloantigen priming was not limited to PIC/KEL enhancement of anti-HOD alloantibody formation, as HOD-reactive CD4+ T cells enhanced anti-glycophorin A (anti-GPA) antibody formation in the absence of inflammation following transfusion of RBCs coexpressing GPA and HOD. These results demonstrate that immune priming to one RBC alloantigen can directly enhance a humoral response to a completely different RBC alloantigen, providing a potential explanation for why alloantibody responders may exhibit increased immune responsiveness to additional RBC alloantigens following subsequent transfusion.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29365318      PMCID: PMC5787868          DOI: 10.1182/bloodadvances.2017010124

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  64 in total

1.  Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements.

Authors:  M J Barnden; J Allison; W R Heath; F R Carbone
Journal:  Immunol Cell Biol       Date:  1998-02       Impact factor: 5.126

2.  Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease.

Authors:  Ross M Fasano; Garrett S Booth; Megan Miles; Liping Du; Tatsuki Koyama; Emily Riehm Meier; Naomi L C Luban
Journal:  Br J Haematol       Date:  2014-09-26       Impact factor: 6.998

3.  HLA-DRB1 alleles and Jk(a) immunization.

Authors:  Denis Reviron; Isabelle Dettori; Virginie Ferrera; Dominique Legrand; Mhammed Touinssi; Pierre Mercier; Philippe de Micco; Jacques Chiaroni
Journal:  Transfusion       Date:  2005-06       Impact factor: 3.157

4.  Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases.

Authors:  H Schonewille; H L Haak; A M van Zijl
Journal:  Transfusion       Date:  1999-07       Impact factor: 3.157

5.  Association of HLA-DRB1 and HLA-DQB1 with red-blood-cell alloimmunization in the Czech population.

Authors:  A Maluskova; F Mrazek; M Pauliskova; P Kovarova; M Koristka; P Jindra; Z Cermakova
Journal:  Vox Sang       Date:  2017-01-04       Impact factor: 2.144

6.  Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications.

Authors:  Oswaldo Castro; S Gerald Sandler; Patricia Houston-Yu; Sohail Rana
Journal:  Transfusion       Date:  2002-06       Impact factor: 3.157

7.  Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models.

Authors:  Jin Yu; Susanne Heck; Karina Yazdanbakhsh
Journal:  Am J Hematol       Date:  2007-08       Impact factor: 10.047

8.  Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells.

Authors:  Jeanne E Hendrickson; Traci E Chadwick; John D Roback; Christopher D Hillyer; James C Zimring
Journal:  Blood       Date:  2007-06-25       Impact factor: 22.113

9.  Red cell alloimmunization in multitransfused HLA-typed patients.

Authors:  S G Brantley; G Ramsey
Journal:  Transfusion       Date:  1988 Sep-Oct       Impact factor: 3.157

10.  Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin.

Authors:  P A Scherle; W Gerhard
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Transfusion-related red blood cell alloantibodies: induction and consequences.

Authors:  Christopher A Tormey; Jeanne E Hendrickson
Journal:  Blood       Date:  2019-02-26       Impact factor: 22.113

2.  Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice.

Authors:  Connie M Arthur; Jerry William L Allen; Hans Verkerke; Justin Yoo; Ryan P Jajosky; Kathryn Girard-Pierce; Satheesh Chonat; Patricia Zerra; Cheryl Maier; Jen Rha; Ross Fasano; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Blood Adv       Date:  2021-01-26

3.  Antibody-mediated immune suppression by antigen modulation is antigen-specific.

Authors:  Cheryl L Maier; Amanda Mener; Seema R Patel; Ryan P Jajosky; Ashley L Bennett; Connie M Arthur; Jeanne E Hendrickson; Sean R Stowell
Journal:  Blood Adv       Date:  2018-11-13

4.  Allogeneic major histocompatibility complex antigens are necessary and sufficient for partial tolerance induced by transfusion of pathogen reduced platelets in mice.

Authors:  Johnson Q Tran; Marcus O Muench; John W Heitman; Rachael P Jackman
Journal:  Vox Sang       Date:  2019-02-07       Impact factor: 2.144

Review 5.  Transfusion Support of Minority Patients: Extended Antigen Donor Typing and Recruitment of Minority Blood Donors.

Authors:  Jenna Khan; Meghan Delaney
Journal:  Transfus Med Hemother       Date:  2018-07-19       Impact factor: 3.747

6.  Examination of Whole-Cell Galectin Binding by Solid Phase and Flow Cytometric Analysis.

Authors:  Anne Leppänen; Connie M Arthur; Sean R Stowell; Richard D Cummings
Journal:  Methods Mol Biol       Date:  2022

7.  Evaluation of the Bactericidal Activity of Galectins.

Authors:  Nourine A Kamili; Anu Paul; Shang-Chuen Wu; Marcelo Dias-Baruffi; Richard D Cummings; Connie M Arthur; Sean R Stowell
Journal:  Methods Mol Biol       Date:  2022

8.  Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion.

Authors:  Seema R Patel; David R Gibb; Kathryn Girard-Pierce; Xiaoxi Zhou; Lilian Cataldi Rodrigues; Connie M Arthur; Ashley L Bennett; Ryan P Jajosky; Megan Fuller; Cheryl L Maier; Patricia E Zerra; Satheesh Chonat; Nicole H Smith; Christopher A Tormey; Jeanne E Hendrickson; Sean R Stowell
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

9.  Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation.

Authors:  Patricia E Zerra; Connie M Arthur; Satheesh Chonat; Cheryl L Maier; Amanda Mener; Sooncheon Shin; Jerry William L Allen; W Hunter Baldwin; Courtney Cox; Hans Verkerke; Ryan P Jajosky; Christopher A Tormey; Shannon L Meeks; Sean R Stowell
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

10.  Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice.

Authors:  Vicente Escamilla-Rivera; Jingchun Liu; David R Gibb; Manjula Santhanakrishnan; Dong Liu; James E Forsmo; Stephanie C Eisenbarth; Ellen F Foxman; Sean R Stowell; Chance John Luckey; James C Zimring; Krystalyn E Hudson; Jeanne E Hendrickson
Journal:  Blood       Date:  2020-05-28       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.